Announcement

Fish Drug Analysis—Phish-Pharm: 2011 Update

Renate Reimschuessel^{1,2}

The searchable fish pharmacokinetics database “Fish Drug Analysis—Phish-Pharm 2011” has been updated and posted online at: <http://www.fda.gov/AnimalVeterinary/ScienceResearch/ToolsResources/Phish-Pharm/default.htm>.

Phish-Pharm was first released in 2005, accompanying an article in the American Association of Pharmaceutical Scientists (AAPS) Journal, “Fish Drug Analysis—Phish-Pharm: A Searchable Database of Pharmacokinetics Data in Fish,” by R. Reimschuessel, L. Stewart, E. Squibb, K. Hirokawa, T. Brady, D. Brooks, B. Shaikh, C. Hodsdon, AAPS Journal. 2005;07(02):E288–E327, article 30 (<http://www.aapsj.org/view.asp?art=aapsj070230>).

The database can be freely downloaded in the form of a Microsoft Office Access file in which multiple parameters can be easily searched, a stand-alone Access Application, or an Excel spreadsheet. In addition, a 508 compliant searchable version for key works is also now available at <http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?rpt=phishPharmListing>.

This information in the database was gathered from over 500 articles, including data from 124 species (95 genera). Data fields include genus, species, water temperatures, the average animal weight, sample types analyzed, drug (or chemical) name, dosage, route of administration, metabolites identified, method of analysis, protein binding, clearance, volume of distribution in a central compartment (Vc) or volume of distribution at steady-state (Vd), and drug half-lives ($t_{1/2}$). Additional fields list the citation, authors, title, and Internet links. The document will be periodically updated, and users are invited to submit additional data.

Additional updates will be announced as they are available. This database is a valuable resource to investigators of drug metabolism in aquatic species as well as government and private organizations involved in the drug approval process for aquatic species.

¹ FDA, Laurel, Maryland, USA.

² To whom correspondence should be addressed. (e-mail: renate.reimschuessel@fda.hhs.gov)